HCG18 and Miyoshi myopathy: In spite of the lower numerosity and disease severity in the MM cohort compared to the PSD one, we observed decreased levels of HCG18-244 in non-surviving (Fig. 6A) and critical (Fig. 6B) patients and of lncCEACAM21 in non-surviving patients (Fig. 6C) compared to relevant controls.